Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2018

Liu Shengwu, Li Shuai, Hai Josephine, Wang Xiaoen, Chen Ting, Quinn Max M, Gao Peng, Zhang Yanxi, Ji Hongbin, Cross Darren A E, Wong Kwok-Kin

Abstract excerpt

Purpose:HER2 (or ERBB2) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas. HER2 amplification is also an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI). However, due to limited preclinical studies and clinical trials, currently there is still no available standard of care for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Copy Number Variations

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29298799
DOI: 10.1158/1078-0432.CCR-17-1875
PMCID: PMC6434713

Genes

EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.PMID 29298799Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.Semantic proximity Read ↗

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.Semantic proximity Read ↗

HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancerSemantic proximity Read ↗

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Semantic proximity Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.